Samuel Agresta
2021
In 2021, Samuel Agresta earned a total compensation of $1.8M as Chief Medical Officer at Foghorn Therapeutics, a 72% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $257,100 |
|---|---|
| Option Awards | $1,124,004 |
| Salary | $428,500 |
| Total | $1,809,604 |
Agresta received $1.1M in option awards, accounting for 62% of the total pay in 2021.
Agresta also received $257.1K in non-equity incentive plan and $428.5K in salary.
Rankings
In 2021, Samuel Agresta's compensation ranked 6,425th out of 12,415 executives tracked by ExecPay. In other words, Agresta earned more than 48.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,425 out of 12,415 | 48th |
Division Manufacturing | 2,748 out of 5,501 | 50th |
Major group Chemicals And Allied Products | 1,212 out of 2,371 | 49th |
Industry group Drugs | 1,080 out of 2,092 | 48th |
Industry Pharmaceutical Preparations | 782 out of 1,542 | 49th |
Source: SEC filing on April 29, 2022.
Agresta's colleagues
We found three more compensation records of executives who worked with Samuel Agresta at Foghorn Therapeutics in 2021.